Oncoinvent

ONCIN.OLPhase 2

Oncoinvent is a Norwegian clinical-stage radiopharmaceutical company developing Radspherin, a novel alpha-emitting microparticle therapy designed to treat cancers that have spread to body cavities. Founded in Oslo, the company's proprietary technology uses calcium carbonate microparticles containing radium-224 to deliver targeted alpha radiation directly to cancer cells while minimizing damage to healthy tissue. The company's lead candidate Radspherin has received FDA Fast Track Designation for peritoneal carcinomatosis from ovarian cancer and is currently in a randomized Phase 2b trial across the US and Europe. Early clinical data has been highly encouraging, with no dose-limiting toxicity observed at the recommended dose. Oncoinvent is publicly traded on the Oslo Stock Exchange (ticker: OCI) and is actively seeking strategic partnerships to expand its pipeline.

Founded

2009

Employees

10-50

Focus

RadiopharmaceuticalsSmall Molecules

ONCIN.OL · Stock Price

USD 189663.66+53641.81 (+39.44%)

Historical price data

AI Company Overview

Technology Platform

Alpha-emitting calcium carbonate microparticles containing radium-224 for targeted local treatment of cancers in body cavities

Pipeline Snapshot

3 drugs in pipeline

Drug	Indication	Stage
Radspherin	Peritoneal Carcinomatosis	Phase 2
Radspherin	Peritoneal Carcinoma	Phase 1/2
Radspherin	Peritoneal Carcinomatosis	Phase 1

Funding History

Total raised: $30M

IPOUndisclosedUndisclosedJun 15, 2021

Series B$30MKreos CapitalJun 15, 2019

Opportunities

First-in-class alpha-emitting therapy for peritoneal cancers.

Large addressable market (~130K new patients/year in US for ovarian + colorectal peritoneal metastasis).

FDA Fast Track designation accelerates regulatory pathway.

Platform extensible to other body cavities.

Hot M&A sector for radiopharmaceuticals.

Risk Factors

Single-asset company dependent on Radspherin platform.

Phase 2b trial is first randomized controlled study — efficacy unconfirmed at scale.

Manufacturing complexity of radioactive microparticles.

Limited financial runway as a small-cap public company.

Niche indication limits addressable market vs systemic radiopharmaceuticals.

Competitive Landscape

Competing in radiopharmaceutical space alongside Novartis (Pluvicto), RayzeBio/BMS (Ac-225 programs), Fusion/AstraZeneca (alpha ADCs). Differentiated by direct instillation approach rather than systemic delivery. Limited direct competitors in peritoneal cavity-specific alpha therapy.